Not Signed In -
Gastrointestinal |
|
|
Clinical Trial: Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
This study is not yet open for patient recruitment.
|
Purpose
The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers. Secondly, tumor response to the combined treatment, drug levels in the body, and drug interactions will be evaluated.
| Condition | Intervention | Phase |
|---|---|---|
| Breast Neoplasms Ovarian Neoplasms Prostatic Neoplasms Lung Neoplasms Gastrointestinal Neoplasms | Drug: Motexafin Gadolinium | Phase I |
MedlinePlus related topics: Breast Cancer; Cancer; Cancer Alternative Therapy; Digestive Diseases; Lung Cancer; Ovarian Cancer; Prostate Cancer
Genetics Home Reference related topics: breast cancer
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel Chemotherapy in the Treatment of Advanced Solid Tumors
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- At least 18 years old
- Metastatic, or unresectable solid tumors from breast, head, and neck, gastrointestinal, genitourinary, lung, or ovarian cancer or recurrent glioblastoma multiforme
- ECOG performance status score either 0, 1, or 2
- Willing and able to provide written informed consent
Exclusion Criteria:
- Greater than two prior cytotoxic regimens
- Laboratory values showing adequate function of bone marrow, liver, and kidneys
- Uncontrolled hypertension
- Known sensitivity to or intolerable adverse effects from taxanes (eg. paclitaxel, docetaxel) or polysorbate 80
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00120939
France Bui, MD 877.676.0330 MedicalAffairs@pcyc.com
Cindy Cheng, PharmD 877.676.0330 MedicalAffairs@pcyc.com
Cindy Cheng, PharmD 877.676.0330 MedicalAffairs@pcyc.com
Pennsylvania
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15213, United States
Gurkamal Chatta, MD
Study chairs or principal investigators
Gurkamal Chatta, MD, Principal Investigator, University of Pittsburgh Medical Center
More Information
Study ID Numbers: PCYC-0212
Record last reviewed: July 2005
Last Updated: July 25, 2005
Record first received: July 18, 2005
ClinicalTrials.gov Identifier: NCT00120939
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-07-26
Record last reviewed: July 2005
Last Updated: July 25, 2005
Record first received: July 18, 2005
ClinicalTrials.gov Identifier: NCT00120939
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-07-26
Resources
- Gastrointestinal (HealthWorld)
email this page
print this page
bookmark this page
feedback on this page
